Foghorn Therapeutics Inc. (FHTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.57 per share a year ago.
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)
The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago.
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
The consensus price target hints at an 81.2% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
